Crinetics enters ATM equity offering agreement for up to $350M

Crinetics Pharmaceuticals, Inc.

Filed prospectus supplement registering up to $350M in common stock sales.
Agents Leerink Partners and Cantor Fitzgerald will receive 3.0% commission per share sold.
No minimum sales required; sales made via 'at-the-market' methods under Rule 415.
Agreement dated June 21, 2024; no escrow or trust arrangement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.